Citalopram vs Clomipramine vs Placebo in Recurrent Depression

This study has been completed.
Danish University Antidepressant Group
Information provided by (Responsible Party):
University of Aarhus Identifier:
First received: April 10, 2012
Last updated: NA
Last verified: April 2012
History: No changes posted
citalopram and clomipramine are better than placebo in preventing new episodes of depression in patients with recurrent depression

Condition Intervention
Drug: Citalopram
Drug: Clomipramine
Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • 2 Hamilton Depression Rating Scale scores of at least 16 with one weeks interval or initiation of another antidepressant treatment [ Time Frame: 2 years of follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Study termination due to adverse event or non-compliance [ Time Frame: 2 years of follow-up ] [ Designated as safety issue: Yes ]

Enrollment: 59
Study Start Date: October 1997
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: citalopram
Drug: Citalopram
Active Comparator: clomipramnine
Drug: Clomipramine
Placebo Comparator: placebo
Drug: placebo


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with recurrent depression
  • Sustained response achieved (3 consecutive monthly ratings at the HDS below 13)after a treatment requiring index episode

Exclusion Criteria:

  • Contraindications to study medications
  • Pregnancy
  • Substance abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: University of Aarhus Identifier: NCT01575158     History of Changes
Other Study ID Numbers: DUAG-5 
Study First Received: April 10, 2012
Last Updated: April 10, 2012
Health Authority: Denmark: Danish Medicines Agency

Additional relevant MeSH terms:
Behavioral Symptoms
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents, Tricyclic
Antiparkinson Agents
Autonomic Agents
Cholinergic Agents
Cholinergic Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors processed this record on May 30, 2016